Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
76-90 of 4175 results
Elite reports topline results from bioequivalence fed study for SequestOx
Elite Pharmaceuticals has reported topline results from a pivotal bioequivalence fed study for SequestOx.
Contract Research & Services > Clinical Trials > News
Alnylam, Sanofi begin clinical trial program of hemophilia treatment fitusiran
By PBR Staff Writer
Alnylam Pharmaceuticals and Sanofi Genzyme have commenced Atlas Phase 3 clinical program for hemophilia treatment, fitusiran.
Contract Research & Services > Clinical Trials > News
Entasis, GARP to start phase 3 trials of drug-resistant gonorrhea antibiotic
By PBR Staff Writer
Entasis Therapeutics and Global Antibiotic Research and Development Partnership (GARDP) will initiate pivotal trials of oral antibiotic zoliflodacin (ETX0914) being developed to treat drug-resistant gonorrhea.
Contract Research & Services > Clinical Trials > News
Prothena commences phase 2 trial of Parkinson's disease drug
Prothena has reported that the first patient has been enrolled in PASADENA, a global Phase 2 study of PRX002/RG7935 in patients with early Parkinson's disease.
Contract Research & Services > Clinical Trials > News
Auris Medical completes patient enrollment for phase 3 trial of Am-111 to treat sudden deafness
Auris Medical has completed patient enrollment in the Phase 3 HEALOS clinical trial of AM-111 in idiopathic sudden sensorineural hearing loss (ISSNHL), also known as sudden deafness.
Contract Research & Services > Clinical Trials > News
FDA puts clinical hold on Merck’s three blood cancer trials
By PBR Staff Writer
The US Food and Drug Administration (FDA) has placed a clinical hold on three combination studies of Merck’s Keytruda (pembrolizumab) for the treatment of blood cancer.
Contract Research & Services > Clinical Trials > News
Zealand Pharma starts phase 3 trial of dasiglucagon to treat severe hypoglycemia in diabetes
Zealand Pharma has started a multinational Phase 3 clinical trial of dasiglucagon in four countries (Austria, Germany, Canada and the US).
Contract Research & Services > Clinical Trials > News
Daiichi Sankyo’ pain drug mirogabalin meets primary end point in Neucourse phase 3 study
By PBR Staff Writer
Daiichi Sankyo's pain drug mirogabalin has showed mixed results in phase 3 global clinical development program.
Contract Research & Services > Clinical Trials > News
Chi-Med, AstraZeneca start phase III trial of savolitinib in papillary renal cell carcinoma
By PBR Staff Writer
Chi-Med and AstraZeneca have commenced a phase 3 study of their c-MET receptor tyrosine kinase inhibitor savolitinib for the treatment of papillary renal cell carcinoma (PRCC).
Contract Research & Services > Clinical Trials > News
Merck’s CETP inhibitor Anacetrapib meets primary end point in REVEAL study
Merck announced that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events (defined as the composite of coronary death, myocardial infarction, and coronary revascularization) compared to placebo in patients at risk for cardiac events who are already receiving an effective LDL-C lowering regimen.
Contract Research & Services > Clinical Trials > News
bluebird unveils topline interim data from Starbeam study of Lenti-D in CALD
bluebird bio has released topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating its investigational gene therapy Lenti-D in under-18 boys with cerebral adrenoleukodystrophy (CALD).
Contract Research & Services > Clinical Trials > News
Roche's emicizumab shows substantial reduction in bleeds in phase III studies
By PBR Staff Writer
Roche’s haemophilia A drug emicizumab has showed a significant effect in the phase III Haven 1 and Haven 2 studies.
Contract Research & Services > Clinical Trials > News
Novartis’ heart drug canakinumab meets primary endpoint in phase III study
By PBR Staff Writer
Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study.
Contract Research & Services > Clinical Trials > News
GSK’s shingles vaccine Shingrix succeeds in phase 3 revaccination trial
By PBR Staff Writer
GSK’s shingles vaccine candidate Shingrix (HZ/su) met its primary objective of inducing a strong immune response in older patients in a phase 3 revaccination trial.
Contract Research & Services > Clinical Trials > News
ImmunoCellular to suspend patient randomization in ICT-107 phase 3 trial
ImmunoCellular Therapeutics has provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma.
Contract Research & Services > Clinical Trials > News
76-90 of 4175 results